Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...
chromatographyonline2d
Characterizing Antibody-Drug Conjugates Using Mass Spectrometry
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...
Roche Receives FDA Approval For The First Companion Diagnostic To Identify Patients With HER2-Ultralow Metastatic Breast Cancer Eligible For ENHERTU
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
Medscape1h
Three Cancer Medicines Green-Lighted in Europe
The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...
AstraZeneca, Daiichi win EU backing for breast cancer drug Dato-DXd
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that ...
Business Wire10h
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
FiercePharma3d
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...
Genmab's SWOT analysis: antibody specialist's stock faces post-Darzalex challenge
Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for cancer treatment, finds itself at a crucial juncture. With a strong portfolio of approved medicines ...